Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.85 |
| ▸ | F2 | P00734 | 2/20 | 0.85 |
| ▸ | F5 | P12259 | 1/20 | 0.85 |
| ▸ | PLAT | P00750 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12036431 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL13379592 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL10044356 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL10044358 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL10044354 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL1253575 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL10044357 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL14198192 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL12761845 | 1.00 | F10 (0.85) | F10F2F5PLAT | |
| SCHEMBL10044355 | 1.00 | F10 (0.85) | F10F2F5PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053349-A1 | OXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053349-A1 | OXAMIDE DERIVATIVE | SULT1E1, PKD2, PKD1 | F10 1005/4885F2 107/4885F5 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.